2018 IMPAACT Annual Meeting Tuberculosis Scientific Committee Presentations

Tuberculosis Scientific Committee

Monday, 18 June 2018

Welcome and Overview of Tuberculosis Scientific Agenda

Anneke Hesseling and Amita Gupta


Pediatric Trials for Multidrug-Resistant Tuberculosis

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIVUninfected Infants, Children and Adolescents with MDR-TB Disease


Anneke Hesseling

IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB


Ethel Weld

IMPAACT 2020: Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-center Trial

Anthony Garcia-Prats

Drug Susceptible TB: Opportunities and Priorities

Tuberculosis Scientific Committee


Lessons Learned and Future Directions for TB Pregnancy Trials

Update and Way Forward for Phase I/II Maternal and Pediatric Prevention Studies:

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-infected Women in High TB Incidence Settings

A5279: One month of Rifapentine/Isoniazid to Prevent TB in People with HIV: BRIEF-TB



Amita Gupta


IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection


Jyoti Mathad

P1026s: Pharmacokinetic Properties of Antiretroviral Therapy during Pregnancy

Jennifer Hughes

TB Pregnancy Registry

Tuberculosis Scientific Committee


Future Opportunities and Priorities for the TB SC

Innovative statistical methods for Phase III Tuberculosis Trials in Children

Soyeon Kim

State of the Art: TB drug pharmacokinetics at the site of disease

Veronique Dartois

Regulatory Perspectives from the FDA on Priorities and Methods for TB Trials in Children and Pregnant Women

Lynne Yao

Roundtable Discussion: Future MDR-TB Trials

Tuberculosis Scientific Committee